Prevention and Immunization, the Key to Achieve a More Efficient Healthcare System Worldwide
Experts in vaccination from Germany, France and Spain, invited by the Bamberg Foundation, met in Berlin to discuss the key...
Vaccine
Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab...
Male Plus Founder Tim Torfs on How Stress Affects Performance in the Bedroom
The Belgian Fitness Entrepreneur Dishes on the Pandemic, Stress, and How It Inspired Him to Create Belgium’s First Natural Libido...
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Emergex Appoints Sir Michael Rake as Board Chairman
Highly experienced international Board Leader joins Emergex as the company grows and progresses clinical development of its pipeline of T...
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a...
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s...
New research finds Imprivata digital identity solutions accelerated emergency COVID-19 vaccine delivery for Northern Ireland Public Health Service
The company’s single sign-on and identity governance solutions helped Health and Social Care (HSC) Trust onboard 500 personnel in under...
Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
Vaccines Investor EventVaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease Sanofi reaffirms ambition to...
Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform
CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a...
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
Dengue is a mosquito-borne viral infection listed by WHO as top 10 threat for global health The government grant is...
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend upon the outcome of secondary...
Ocean Biomedical, Inc. Joins the Russell 2000® Index
Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting...
Emergent BioSolutions Announces CEO Transition
Robert G. Kramer Sr. to Retire Haywood Miller to Serve as Interim CEO GAITHERSBURG, Md., June 27, 2023 (GLOBE NEWSWIRE)...
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the...
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE...
Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most...
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients...
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration
- Sutro will receive $140 million upfront and is eligible to receive up to an additional $250 million in future...
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an...